...
首页> 外文期刊>Toxicological sciences: An official journal of the Society of Toxicology >Evaluation of the Relative Performance of Pancreas-Specific MicroRNAs in Rat Plasma as Biomarkers of Pancreas Injury
【24h】

Evaluation of the Relative Performance of Pancreas-Specific MicroRNAs in Rat Plasma as Biomarkers of Pancreas Injury

机译:评价大鼠血浆胰腺特异性微小RNA的相对性能作为胰腺损伤的生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Drug-induced pancreatic injury (DIPI) has become linked in recent years to many commonly prescribed medications from several pharmacological classes. Diagnosis is currently most often focused on identification of acute pancreatitis and generally based on subjective clinical assessment and serum amylase and lipase enzymatic activity, which have been criticized as being insufficiently sensitive and specific. The lack of novel noninvasive biomarkers of DIPI can impede the advancement of drug candidates through nonclinical development and translation into clinical settings. Pancreas-specific microRNAs (miRNAs) are currently being evaluated as biomarkers of DIPI that may outperform and/or add value to the interpretation of amylase and lipase. To assess the relative performance of these novel miRNAs, a comprehensive evaluation was conducted to determine the sensitivity and specificity of detecting DIPI in rats. Four miRNAs were evaluated (miR-216a-5p, miR-216b-5p, miR-217-5p, and miR-375-3p) in plasma from 10 studies in which rats were treated with known pancreatic toxicants to assess sensitivity, and from 10 different studies in which toxicity was evident in tissues other than pancreas to assess specificity. The candidate miRNA biomarker performance was compared with amylase and lipase, and receiver operator characteristics (ROC) were determined. Analysis of ROCs demonstrated that all four miRNAs outperformed amylase and lipase in monitoring acute pancreatic injury defined as acinar cell degeneration/necrosis. Specifically, miR-217-5p had the highest performance among all biomarkers assessed. The increased sensitivity and specificity of these miRNAs support their use as biomarkers of DIPI, thereby adding value to the interpretation of amylase and lipase measurements in nonclinical studies. The potential for miRNAs to serve as translational biomarkers in the clinic for the monitoring of DIPI is also supported by this investigation.
机译:近年来,药物诱导的胰腺损伤(DIPI)已与来自几种药理课程的许多通常规定的药物联系在一起。诊断目前最常集中在鉴定急性胰腺炎,通常基于主观临床评估和血清淀粉酶和脂肪酶酶活性,这被批评为不充分敏感和特异性。缺乏DIPI的新型非侵入性生物标志物可以通过非临床发育和翻译进入临床环境来妨碍毒品候选者的进步。目前正在评价胰腺特异性微小RNA(miRNA)作为DIPI的生物标志物,其可能优于和/或增加淀粉酶和脂肪酶的解释。为了评估这些新型miRNA的相对性能,进行了综合评价,以确定检测大鼠DIPI的敏感性和特异性。评估四种miRNA(miR-216a-5p,miR-216b-5p,miR-217-5p和miR-375-3p,miR-375-3p),其10项研究,其中用已知的胰腺毒性处理大鼠以评估敏感性,以及来自10种不同的研究,其中在胰腺以外的组织中明显明显,以评估特异性。将候选MiRNA生物标志物性能与淀粉酶和脂肪酶进行比较,并且测定接收器操作员特性(ROC)。 Roc的分析证明,所有四种MiRNA都不表现出淀粉酶和脂肪酶,监测急性胰腺损伤定义为acinar细胞变性/坏死。具体而言,MIR-217-5P在评估的所有生物标志物之间具有最高的性能。这些miRNA的敏感性和特异性的增加支持它们用作DIPI的生物标志物,从而增加了非临床研究中淀粉酶和脂肪酶测量的解释的价值。该调查还支持MIRNA作为诊所中临床中的翻译生物标志物的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号